All In Biotech

Drug Trial Radar · NCT06630299

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 8, 2024

Primary completion

Apr 23, 2026

Study completion Aug 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard of care treatment in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on a stable standard of care regimen for ≥ 6 months prior to screening. The standard of care includes 2 or 3 medicines, antiretroviral agents (ARVs). The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.

Conditions

  • HIV-1-Infection

Interventions

  • ISL/LENDrug

    Tablet administered orally

  • Antiretroviral CombinationsDrug

    2 or 3 antiretrovirals (ARVs) administered as defined by the investigator, according to the prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-defined Snapshot AlgorithmTime frame: Week 48

Locations

100 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham(UAB) 1917 Research Clinic

    Birmingham, Alabama

  • Pueblo Family Physicians

    Phoenix, Arizona

  • Vv-Tmf-5366229

    Los Angeles, California

  • Ruane Clinical Research Group

    Los Angeles, California

  • BIOS Clinical Research

    Palm Springs, California

  • Vivent Health

    Denver, Colorado

  • University of Colorado Clinical and Translational Research Center

    Denver, Colorado

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Aids Healthcare Foundation - Northpoint

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • CAN Community Health

    Miami Gardens, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • AHF Pensacola

    Pensacola, Florida

  • CAN Community Health

    Sarasota, Florida

  • BayCare Health System, Inc./St. Joseph's Hospital

    Tampa, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Metro Infectious Disease Consultants, P.L.L.C.

    Decatur, Georgia

  • Mercer University, Department of Internal Medicine

    Macon, Georgia

  • Chatham County Health Department

    Savannah, Georgia

  • Howard Brown Health Center

    Chicago, Illinois

  • Indiana CTSI Clinical Research Center

    Indianapolis, Indiana

  • Brigham and Womens's Hospital

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Community Research Initiative of New England d/b/a Community Resource Initiative (CRI)

    Boston, Massachusetts

  • Be Well Medical Center

    Berkley, Michigan

  • Henry Ford Health

    Detroit, Michigan

  • Trinity Health Michigan d/b/a Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan

  • ID Care

    Hillsborough, New Jersey

  • Saint Michael's Medical Center

    Newark, New Jersey

  • AXCES Research Group, LLC

    Santa Fe, New Mexico

  • NewYork-Presbyterian Queens

    Flushing, New York

  • Northwell Health/Division of Infectious Diseases

    Manhasset, New York

  • Jacobi Medical Center

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Health System(DUHS)

    Durham, North Carolina

  • ECU Health Leo Jenkins Cancer Building

    Greenville, North Carolina

  • Rosedale Health and Wellness

    Huntersville, North Carolina

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio

  • Prisma Health Midlands - Clinical Research Unit

    Columbia, South Carolina

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.